Liver transplantation in the United States, 1999-2008.

PubWeight™: 3.92‹?› | Rank: Top 1%

🔗 View Article (PMID 20420649)

Published in Am J Transplant on April 01, 2010


P J Thuluvath1, M K Guidinger, J J Fung, L B Johnson, S C Rayhill, S J Pelletier

Author Affiliations

1: Mercy Medical Center, Baltimore, MD, USA.

Articles citing this

Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99

Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65

Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate. J Hepatol (2014) 3.88

MELD Exceptions and Rates of Waiting List Outcomes. Am J Transplant (2011) 2.47

Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology (2014) 2.17

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07

An examination of liver offers to candidates on the liver transplant wait-list. Gastroenterology (2012) 2.03

Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis. Am J Transplant (2013) 2.02

Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl (2016) 1.67

Development of organ-specific donor risk indices. Liver Transpl (2012) 1.26

Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatr (2011) 1.20

Model for end-stage liver disease: end of the first decade. Clin Liver Dis (2011) 1.20

Current and future disease progression of the chronic HCV population in the United States. PLoS One (2013) 1.17

Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09

Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health (2011) 1.06

Prioritization for liver transplantation. Nat Rev Gastroenterol Hepatol (2010) 1.05

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health (2013) 1.01

Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol (2013) 1.01

Impact of the center on graft failure after liver transplantation. Liver Transpl (2013) 0.98

Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer (2013) 0.97

Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology (2016) 0.95

Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y) (2013) 0.94

Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol (2013) 0.94

Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis. Am J Transplant (2012) 0.92

Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl (2012) 0.91

Pretransplant fasting glucose predicts new-onset diabetes after liver transplantation. J Transplant (2012) 0.90

Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. HPB (Oxford) (2011) 0.90

Direct reprogramming of human fibroblasts to hepatocyte-like cells by synthetic modified mRNAs. PLoS One (2014) 0.88

Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88

Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl (2012) 0.88

Liver Transplantation for Cholestatic Liver Diseases in Adults. Clin Liver Dis (2015) 0.88

Excellent long-term patient and graft survival are possible with appropriate use of livers from deceased septuagenarian and octogenarian donors. HPB (Oxford) (2014) 0.88

Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl Int (2015) 0.87

The evolution in the prioritization for liver transplantation. Ann Gastroenterol (2012) 0.87

Optofluidic phantom mimicking optical properties of porcine livers. Biomed Opt Express (2011) 0.86

Exception point applications for 15 points: an unintended consequence of the share 15 policy. Liver Transpl (2012) 0.86

Donor Risk Index for African American liver transplant recipients with hepatitis C virus. Hepatology (2013) 0.84

Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. HPB (Oxford) (2013) 0.84

Standardizing MELD Exceptions: Current Challenges and Future Directions. Curr Transplant Rep (2014) 0.84

Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One (2014) 0.84

Variation in access to the liver transplant waiting list in the United States. Transplantation (2014) 0.83

Is left lobe adult-to-adult living donor liver transplantation ready for widespread use? The US experience (1998-2010). HPB (Oxford) (2012) 0.83

Outcomes of transplantation of livers from donation after circulatory death donors in the UK: a cohort study. BMJ Open (2013) 0.83

A randomized clinical trial testing the anti-inflammatory effects of preemptive inhaled nitric oxide in human liver transplantation. PLoS One (2014) 0.82

Renal outcomes of simultaneous liver-kidney transplantation compared to liver transplant alone for candidates with renal dysfunction. Clin Transplant (2014) 0.81

Inhibition of acidic sphingomyelinase reduces established hepatic fibrosis in mice. Hepatol Res (2014) 0.81

Futility and rationing in liver retransplantation: when and how can we say no? J Hepatol (2012) 0.81

A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients. J Transplant (2012) 0.80

Disparities in liver transplantation: the association between donor quality and recipient race/ethnicity and sex. Transplantation (2014) 0.80

Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80

Expanded criteria donors. Clin Liver Dis (2014) 0.79

Engineered liver for transplantation. Curr Opin Biotechnol (2013) 0.79

Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (2015) 0.79

Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. HPB (Oxford) (2014) 0.79

Reframing the impact of combined heart-liver allocation on liver transplant wait-list candidates. Liver Transpl (2014) 0.79

Donation after cardio-circulatory death liver transplantation. World J Gastroenterol (2012) 0.78

Outcomes of living versus deceased donor liver transplantation for acute liver failure in the United States. Transplant Proc (2014) 0.78

Predicting Liver Transplant Capacity Using Discrete Event Simulation. Med Decis Making (2014) 0.78

Gender-based disparities in access to and outcomes of liver transplantation. World J Hepatol (2015) 0.78

Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? J Oncol (2016) 0.78

Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology (2014) 0.78

Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma. HPB (Oxford) (2014) 0.78

Gray's time-varying coefficients model for posttransplant survival of pediatric liver transplant recipients with a diagnosis of cancer. Comput Math Methods Med (2013) 0.77

Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) (2014) 0.77

Metabolic profiling during ex vivo machine perfusion of the human liver. Sci Rep (2016) 0.77

Warm ischemic injury is reflected in the release of injury markers during cold preservation of the human liver. PLoS One (2015) 0.77

Ethnic disparities in liver transplantation. Gastroenterol Hepatol (N Y) (2011) 0.77

HCV in liver transplantation. Semin Immunopathol (2012) 0.76

Evaluation of liver transplant recipients. J Clin Exp Hepatol (2012) 0.76

Circulating FoxP3+ Regulatory T and Interleukin17-Producing Th17 Cells Actively Influence HBV Clearance in De Novo Hepatitis B Virus Infected Patients after Orthotopic Liver Transplantation. PLoS One (2015) 0.76

Coagulopathy and transfusion therapy in pediatric liver transplantation. World J Gastroenterol (2016) 0.75

Morbidity and Mortality Rounds in Liver Transplantation. Visc Med (2016) 0.75

A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy. J Vasc Interv Radiol (2016) 0.75

Use of Hepatitis C-Positive Donor Livers in Liver Transplantation. Curr Hepatol Rep (2017) 0.75


Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. Clin Diabetes (2017) 0.75

An experience of liver transplantation in Latin America: a medical center in Colombia. Colomb Med (Cali) (2015) 0.75

350-560 μm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: The safety and efficacy. Medicine (Baltimore) (2017) 0.75

A mathematical model for optimizing the indications of liver transplantation in patients with hepatocellular carcinoma. Theor Biol Med Model (2013) 0.75

Hepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant Medicine. Int J Mol Sci (2015) 0.75

Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis. Liver Int (2015) 0.75

Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List. Hepatology (2016) 0.75

Early weight changes after liver transplantation significantly impact patient and graft survival. Eur J Gastroenterol Hepatol (2016) 0.75

Opinion toward living liver donation of hospital personnel from units related to organ donation and transplantation: a multicenter study from Spain and latin-america. Hepat Mon (2014) 0.75

Peritransplant energy changes and their correlation to outcome after human liver transplantation. Transplantation (2017) 0.75

Effectively Screening for Coronary Artery Disease in Patients Undergoing Orthotopic Liver Transplant Evaluation. J Transplant (2016) 0.75

Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. PLoS One (2015) 0.75

A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. BMC Infect Dis (2017) 0.75

Donor Diabetes and Prolonged Cold Ischemia Time Synergistically Increase the Risk of Graft Failure After Liver Transplantation. Transplant Direct (2017) 0.75

Rate and predictors of successful cardiopulmonary resuscitation in end-stage liver disease. Dig Dis Sci (2014) 0.75

Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation. World J Hepatol (2017) 0.75

Differential Simultaneous Liver and Kidney Transplant Benefit Based on Severity of Liver Damage at the Time of Transplantation. Gastroenterology Res (2017) 0.75

Articles by these authors

(truncated to the top 100)

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Survival benefit-based deceased-donor liver allocation. Am J Transplant (2009) 2.89

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med (2001) 2.41

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24

Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22

Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12

Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin preservation in renal transplantation. Am J Transplant (2007) 2.10

One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

Persistent occult hypoperfusion is associated with a significant increase in infection rate and mortality in major trauma patients. J Trauma (2000) 2.09

The side effects of FK 506 in humans. Transplant Proc (1990) 2.08

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant (2008) 2.04

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95

Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94

FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94

Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88

Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86

Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83

Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82

Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81

Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80

Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

Transplantation. JAMA (1990) 1.71

Dobutamine stress echocardiography for preoperative cardiac risk stratification in patients undergoing orthotopic liver transplantation. Liver Transpl Surg (1998) 1.70

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70

Recovery and utilization of deceased donor kidneys from small pediatric donors. Am J Transplant (2006) 1.68

Is living donor nephrectomy a "23-hr stay" procedure? Transplantation (1999) 1.68

A technique for management of multiple renal arteries after laparoscopic donor nephrectomy. Transplantation (1997) 1.67

Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol (1985) 1.65

Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61

Clinical characteristics and antibiotic utilization in surgical patients with Clostridium difficile-associated diarrhea. Am Surg (1999) 1.61

Distinctive clinical features of portopulmonary hypertension. Chest (1997) 1.59

Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59

Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation (1995) 1.59

The spectrum of portal vein thrombosis in liver transplantation. Ann Surg (1991) 1.58

Organ donation and utilization, 1995-2004: entering the collaborative era. Am J Transplant (2006) 1.57

De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57

Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57

Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56

Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol (2000) 1.56

Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg (1999) 1.55

Piggyback orthotopic intestinal transplantation. Surg Gynecol Obstet (1993) 1.55

Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant (2007) 1.55

Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation (2000) 1.53

Split tolerance induced by orthotopic liver transplantation in mice. Transplantation (1994) 1.52

A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50

Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology (1994) 1.49

Gender-dependent differences in outcome after the treatment of infection in hospitalized patients. JAMA (1999) 1.49

FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery (1991) 1.49

An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitis. Am J Transplant (2001) 1.48

Pancreas transplantation with enteric drainage under tacrolimus induction therapy. Transplant Proc (1997) 1.48

AvrXa10 contains an acidic transcriptional activation domain in the functionally conserved C terminus. Mol Plant Microbe Interact (1998) 1.45

The virulence factor AvrXa7 of Xanthomonas oryzae pv. oryzae is a type III secretion pathway-dependent nuclear-localized double-stranded DNA-binding protein. Proc Natl Acad Sci U S A (2000) 1.45

Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45

The effects of donor and recipient practices on transplant center finances. Am J Transplant (2008) 1.44

Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene (2007) 1.44

The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg (1998) 1.42

Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol (1997) 1.41

Venous-right atrial bypass for superior vena cava thrombosis during orthotopic liver transplantation. Transplantation (1997) 1.39

Increased late hepatic artery thrombosis rate and decreased graft survival after liver transplants with zero cross-reactive group mismatches. Liver Transpl (2000) 1.39